Dollens, In Final Speech As CEO, Says Industry Should Publicize Device Risks
This article was originally published in The Gray Sheet
Executive Summary
Retired Guidant CEO Ron Dollens says the device industry needs to do a better job educating physicians and patients about the risks associated with implantable devices
You may also be interested in...
J&J Salvages Deal With Guidant: $4 Bil. Shaved Off Purchase Price
Johnson & Johnson's renegotiated deal to acquire Guidant for $21.5 bil. will make medical devices the firm's largest business segment once the merger closes
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.